Your browser is no longer supported. Please, upgrade your browser.
Humanigen, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own40.28% Shs Outstand43.49M Perf Week3.16%
Market Cap980.81M Forward P/E4.60 EPS next Y4.11 Insider Trans-1.52% Shs Float30.83M Perf Month34.76%
Income-59.30M PEG- EPS next Q-0.66 Inst Own31.00% Short Float6.73% Perf Quarter40.77%
Sales- P/S- EPS this Y27.30% Inst Trans1.75% Short Ratio2.48 Perf Half Y-18.45%
Book/sh1.78 P/B10.63 EPS next Y327.10% ROA-174.70% Target Price29.33 Perf Year738.56%
Cash/sh1.76 P/C10.73 EPS next 5Y12.50% ROE-302.90% 52W Range1.55 - 33.95 Perf YTD8.11%
Dividend- P/FCF- EPS past 5Y60.20% ROI- 52W High-44.71% Beta-1.39
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low1110.58% ATR2.19
Employees2 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)58.70 Volatility10.85% 13.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-567.50% Profit Margin- Rel Volume0.43 Prev Close18.92
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume836.43K Price18.77
Recom1.70 SMA202.65% SMA5042.41% SMA20039.99% Volume360,773 Change-0.79%
Dec-23-20Initiated National Securities Buy $35
Dec-22-20Initiated Jefferies Buy $27
Oct-21-20Initiated Cantor Fitzgerald Overweight $25
Oct-14-20Initiated H.C. Wainwright Buy $31
Oct-01-20Initiated ROTH Capital Buy $25
Jan-10-21 08:00AM  
Jan-05-21 04:30PM  
Dec-28-20 07:00AM  
Dec-20-20 03:40AM  
Dec-17-20 08:00AM  
Dec-14-20 08:00AM  
Dec-02-20 11:33PM  
Nov-23-20 04:05PM  
Nov-11-20 07:00AM  
Nov-06-20 09:59AM  
Nov-04-20 04:05PM  
Nov-03-20 09:01AM  
Nov-01-20 05:58AM  
Oct-30-20 02:05PM  
Oct-29-20 07:00AM  
Oct-27-20 04:01PM  
Oct-13-20 12:48PM  
Oct-05-20 10:20AM  
Oct-02-20 08:00AM  
Sep-23-20 07:30AM  
Sep-22-20 04:50PM  
Sep-21-20 12:02PM  
Sep-17-20 09:10PM  
Sep-15-20 07:30AM  
Sep-14-20 07:00AM  
Sep-04-20 05:00PM  
Sep-02-20 06:21PM  
Sep-01-20 06:15PM  
Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NOMIS BAY LTD.10% OwnerJan 19Sale19.8150,000990,5006,173,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 15Sale18.2330,000546,8706,223,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 14Sale18.0725,000451,6506,253,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 12Sale18.4314,577268,6136,278,532Jan 13 05:22 PM
NOMIS BAY LTD.10% OwnerJan 11Sale19.0010,423198,0376,293,109Jan 13 05:22 PM
NOMIS BAY LTD.10% OwnerDec 28Sale22.2050011,1016,303,532Dec 31 04:30 PM
NOMIS BAY LTD.10% OwnerDec 24Sale22.058,401185,2346,304,032Dec 28 05:17 PM
NOMIS BAY LTD.10% OwnerDec 23Sale21.0945,000948,8706,312,433Dec 28 05:17 PM
NOMIS BAY LTD.10% OwnerDec 22Sale20.0050,0001,000,0006,357,433Dec 23 04:06 PM
NOMIS BAY LTD.10% OwnerDec 21Sale19.4625,000486,4456,407,433Dec 23 09:17 AM
NOMIS BAY LTD.10% OwnerDec 18Sale15.7662,700988,3216,469,733Dec 23 09:17 AM